Yves Latour

CREAL develops a unique light-field AR display, blending digital images into the real world without visual conflict. With natural focus and continuous depth resolution, users can enjoy comfortable, extended interaction with virtual objects in the personal space.

Wyden is the global leader in institutional digital asset trading technology. By covering the entire trade lifecycle and supporting seamless custody, core banking and portfolio management system integration as well as full trade lifecycle automation, the Wyden platform streamlines digital assets trading. Engineered by a team of trading system veterans and crypto asset experts, Wyden offers best-in-class integrated infrastructure solutions that meet the highest institutional needs. Wyden has offices in Zurich, New York and Singapore.

Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need.

The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets including orphan GPCRs. InterAx AG has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry.

Commerce is evolving, quickly, everywhere, with a growing gap between included and left behind. KiWi is Mexican start-up that works with distributors and micro-merchants to provide them with access to financial solutions. We offer supply chain financing to distributors, providing loans to their clients to ensure they always have the purchase power to buy supplies. Additionally, we empower micro-merchants with adapted digital technology to accept card payments, make mobile top-ups, and bill payments, while also having access to micro-credits. Our goal is to help businesses thrive by providing them with the tools they need to succeed.

Hylomorph is an innovative Medtech company engineering biomaterials to optimize the interface between implants and their surrounding biological tissues. We aim at preventing post operative complications in implantable medical devices. Our mission is to improve quality of life in patients and the quality of care by health professionals. ​ Our proprietary CellSense technology was developed in the cutting-edge laboratories of the Swiss Federal Institute of Technology (ETH Zurich). Hylomorph's first product, Hylomate, has demonstrated outstanding performance in limiting the foreign body reaction and fibrotic buildup in pre-clinical settings and is currently undergoing first-in-man clinical trials in Germany.

Description Avrios is an award-winning fleet management software. Founded in 2015 in Zurich by a team of serial entrepreneurs, Avrios currently manages the fleet of more than 1.000 customers in Europe and is one of the fastest growing companies in the SaaS space. Our SaaS platform helps companies provide tailored transportation to its employees and thus enables them to attract top talent while keeping their transportation expenditures under control. Fuelled by a passionate, driven and hard-working team, backed by leading venture capital investors and supported by a high calibre board of directors, Avrios is looking to continue this growth journey and help hundreds of thousands of people in Europe move seamlessly. For more information visit us at: http://www.avrios.com/

Luciole Medical AG is developing a unique, next-generation platform of brain monitoring sensors to rapidly provide important information allowing the proper diagnostic and monitoring of compromised oxygen supply conditions and complications. The platform is using proprietary complex algorithm to analyze large set of data and extract clinically relevant information. The company obtained the CE mark for a minimally invasive NIRS probe for ICU and for a NIRS patch for external measurement of brain oxygenation parameters. The Swiss-based private company is a spin out from the Swiss Federal Institute of Technology Zurich (ETH) and the University Hospital of Zurich.

MyCamper is the largest camper sharing platform in Switzerland. We want to revolutionise the camper rental market by opening it up to private offers and consistently focusing on simplicity and personality. In doing so, we create an affordable and original alternative to the commercial offer. MyCamper makes adventure travel and camping dreams come true.

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

COVID-19 Test Centers in Switzerland of highest medical standards. 📍Bern Main Station 📍Zurich Airport

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Connecting players and supporting their passion for the sport GotCourts is a revolutionary social network for racket sports players and online service for booking courts and coaches. It’s the first platform to provide everything a player needs in a single marketplace. Finding a partner or a coach, booking a court nearby or competing for a place in our leaderboards and tracking your progress, GotCourts is your "virtual global club"​. For court facilities and clubs we offer a capable club management system and a platform to engage with the community. Since we started in 2014 we have grown rapidly in Switzerland and are now scaling internationally. GotCourts already connects 160’000 racket sports enthusiasts and supports their passion for the sport.

The Expert Community Solution puts your community at the heart of your shoppers experience. We simplify meaningful human exchanges between experienced product users and shoppers customers directly on your online store - when and where they shop. We believe this is a key differentiator for consumers as synthetic content increases and the trusted connection between consumers becomes less accessible. Our community touchpoints includes live community conversations, community content, and community recommendations. Our technology automatically helps you build a community of knowledgable brand fans, verifying and guaranteeing high-quality community exchanges.

Fashwell recognizes products in images. We’ve spent the last three years developing cutting-edge deep learning algorithms tuned to identify fashion and furniture in images. We leverage this technology to power visual search and recommendations for retailers, brands and more. Our products integrate seamlessly into any platform and are proven to boost conversions, create new revenue channels and increase retention rates. We pride ourselves on our cutting edge deep learning algorithms trained for best-in-class performance in fashion and furniture product recognition. Thanks to our preeminent and easily integrable technology, our customers enjoy fast image processing with accurate and scalable results – without having to worry about the nitty gritty details. Fashwell is a strong team of computer vision experts and eCommerce professionals who are always on the look-out for motivated and like-minded talents. Learn more about jobs at Fashwell here: http://tech.fashwell.com/career/ Alternatively you can get in touch via email: hello@fashwell.com Interested in our products? Request a demo: partnership@fashwell.com

CREAL develops a unique light-field AR display, blending digital images into the real world without visual conflict. With natural focus and continuous depth resolution, users can enjoy comfortable, extended interaction with virtual objects in the personal space.

Wyden is the global leader in institutional digital asset trading technology. By covering the entire trade lifecycle and supporting seamless custody, core banking and portfolio management system integration as well as full trade lifecycle automation, the Wyden platform streamlines digital assets trading. Engineered by a team of trading system veterans and crypto asset experts, Wyden offers best-in-class integrated infrastructure solutions that meet the highest institutional needs. Wyden has offices in Zurich, New York and Singapore.

Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients (non-responders to oral drugs). Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the male population in great need.

The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets including orphan GPCRs. InterAx AG has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry.